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Abstract
The complexity of tumor biology warrants tailored drug delivery for overcoming the major
challenges faced by cancer therapies. The versatility of the PRINT® (Particle Replication In Non-
wetting Templates) process has enabled the preparation of shape- and size-specific particles with a
wide range of chemical compositions and therapeutic cargos. Different particle matrices and drugs
may be combined in a plug-and-play approach, such that physico-chemical characteristics of
delivery vectors may be optimized for biocompatibility, cargo stability and release, circulation
half-life, and efficacy. Thus, the engineering of particles for cancer therapy with specific
biophysical behaviors and cellular responses has been demonstrated via the PRINT process.
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I. Increasing the Efficacy of Particle-Based Therapeutics by Addressing
Tumor Biology
The biggest challenge of nanoparticles (NPs) for the treatment of cancer is penetrating a
tumor microenvironment that is spatially and temporally heterogeneous. Abnormal tumor
vasculature, lack of functional lymphatics, and elevated interstitial fluid pressure (IFP)
reduce the delivery of particles into tumors.1 Blood flow in tumors is highly irregular based
upon the spatial distribution of the vasculature with wide interendothelial junctions, thin and
thick basement membrane, large numbers of fenestrae, and transendothelial channels.
Unperfused tumoral regions create a hostile tumor microenvironment (low partial pressure
of oxygen, low pH, and necrotic tissue) that can lead to drug resistance and tumor
progression (Figure 1).1 There are some primary tumors that are very poorly vascularized,
such as pancreatic cancer, and the hypovascular nature of these tumors limits the ability to
deliver therapeutics in a highly efficient manner.2 Furthermore, the interstitial fluid pressure
(IFP) is uniformly elevated in tumors due to the combination of highly permeable tumor
vasculature and the lack of functional lymphatic tissue in the tumor interstitial space, which
limits drug transport into the center of the tumor.3
The tumor characteristics that create a barrier for particle delivery into tumors are the same
ones that allow for effective particle transport into the tumor. Nanoparticles can extravasate
into tumor tissue from large pores that are present in the tumor vasculature and be retained
within the tumor due to the high IFP; this is known as the enhanced permeation and
retention (EPR) effect. Thus, the EPR effect is utilized as a passive targeting method for
delivery of NPs into tumors. Tumor penetration also requires a long circulation half-life to
allow for extravasation of the particle across the hyper-permeable tumor vessels and
effective diffusion through the tumor interstitial space.4
The PRINT process5 is capable of controlling particle size, shape, surface chemistry,
modulus, matrix, and drug loading. The major barriers for nanoparticle intratumoral
transport may therefore be overcome by tuning the particle physico-chemical characteristics.
For example, a pH-sensitive matrix can be incorporated into the PRINT process for
fabricating particles capable of selective drug release within the acidic tumor
microenvironment and intracellular endosome.6 Additionally, highly flexible particles with
particular dimensions can be fabricated using the PRINT process to improve transport
through the tumor extracellular matrix.7 The dimensions of PRINT particles range from
sub-100 nm to micron-scale sizes with unique shapes such as pollen, toroids, trapezoids,
helicopters, lollipops, cylinders, filamentous particles, and red blood cell mimics. Molecular
conjugates and NPs prepared through other fabrication techniques, e.g. metal NPs, may
adopt smaller sizes than conventional PRINT particles; however, sub-20 nm features have
been replicated.8
II. Extending Circulation Times and Enabling Active Targeting by Modifying
the Particle Surface
Upon contact with the blood stream, the surface of the nanoparticles can become coated with
blood proteins that essentially mark the NPs for clearance from the body. This process is
known as opsonization. In an effort to improve circulation half-life by reducing NP
interactions with blood components and MPS (mononuclear phagocyte system) cells,
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poly(ethylene glycol) (PEG) has been extensively used on a variety of NP systems.9 There is
a general consensus that stealth properties can be achieved by coating NPs with a high
density of PEG of molecular weights ranging from 2 kDa to 10 kDa.9,10 Studies have shown
that these stealth properties not only decrease NP elimination by the MPS system, they
increase passive tumor targeting through the EPR effect.11 There are a number of passively
targeted PEGylated polymeric NPs in early phase clinical trials for treating a variety of
cancers.12 These NPs have clearly demonstrated wider therapeutic windows and lower
systemic toxicities. It is important to note that these passive targeting strategies only
increase accumulation of the drug at the tumor site; however, this extracellular delivery
strategy is less effective for NPs or drugs that are not readily taken up by cancer cells.
Therefore, much effort is now focused on investigating actively targeted NPs to increase
specific cell uptake through receptor-mediated endocytosis.12,13
Active targeting uses affinity ligands to direct the binding of NPs to receptors overexpressed
on diseased tissues and/or cells. These ligands can be antibodies, aptamers, proteins,
peptides, or small molecules.12,13 Methods for preparing these actively targeted NPs involve
either conjugation of targeting ligands to the surface of the NP or through self-assembly
using prefunctionalized copolymers.12,13 Though the platform for an actively targeted NP
was described more than 30 years ago, only a few targeted NPs have entered clinical trials.12
The key challenge for this platform is the ability to balance physico-chemical parameters
that simultaneously confer targeting, stealth properties, and controlled drug release. It has
been demonstrated that as the surface density of ligands is increased, NP surfaces become
less stealth-like, which results in rapid clearance from the blood stream and poor EPR.13
Therefore, having the ability to narrowly optimize surface densities of stealth PEGs and
targeting ligands on a NP is essential for in vivo success and clinical translation.
We demonstrated the ability to precisely control PEG density on the surface of hydrogel
PRINT NPs, ranging from non-PEGylated to PEG mushroom and PEG brush decorated
NPs. Increasing the PEG density on NPs significantly reduced protein adsorption and
macrophage association, and increased circulation half-life.15
We have also shown that PRINT NPs conjugated with human transferrin or transferrin
receptor monoclonal antibody can specifically target a broad spectrum of cancers, making it
a useful platform for targeted drug delivery.16 Moreover, an essentially nontoxic transferrin
and transferrin receptor antibody OKT9 was converted into a potential cancer therapeutic by
harnessing the multivalent effect through conjugation to PRINT NPs.16 As stated above,
having the ability to optimize NP physico-chemical properties is essential for in vivo
success. The PRINT process allows for precise control over surface densities of both stealth
PEG and targeting ligands on NPs, which will enable the optimization of passive and active
targeting for enhanced drug delivery. The density of ligands conjugated to cylindrical
(diameter [d] = 200 nm; height [h] = 200 nm) or rice-shaped (d = 80 nm; h = 320 nm) NPs
was quantified through spectrophotometric measurements for PEGs (using fluorescent
PEGs) and BCA assays for proteins. By controlling the stoichiometric ratio of reactive PEGs
to nanoparticles, the density of ligands was tuned accordingly.15
III. Encapsulating a Wide Variety of Cargos using Different Particle Matrices
The top down fabrication of particles via the PRINT process utilizes chemically resistant
perfluoropolyether-based molds, which allow for the composition to be dictated in a plug-
and-play manner. Inherent solubility issues, e.g. those between hydrophobic and hydrophilic
molecules, may minimize the accessibility of neat particle formulations across all
compositions; however, additives may be implemented to aid in homogenization of certain
formulations. The composition of PRINT particles may be selected for compatibility,
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stability, and efficacy in a given application for the therapeutic cargo encapsulated. Particle
matrices composed of natural and synthetic polymers, pure drugs, and crosslinked networks
have been explored and designed with features for effective delivery (Figure 2). Molds can
be filled with pre-particle components through lamination of a solution or film followed by
solidification (e.g. photochemical curing).
Through the plug-and-play approach enabled by the PRINT process, chemotherapeutics
have been loaded into reductively-labile hydrogel particles, biodegradable polyester
particles, and hydrogel NPs. Doxorubicin, a potent DNA intercalating chemotherapy, was
physically encapsulated in PEG hydrogel particles, prepared by UV-curing molds filled with
a pre-particle solution containing a degradable crosslinker, photoinitiator, and functional
acrylics.17 Amorphous drug-polymer PRINT particles consisting of docetaxel, an anti-
mitotic chemotherapy, and poly(lactide-co-glycolide) (PLGA) achieved encapsulation
efficiencies greater than 90% and drug loadings up to 40 weight percentage (wt %).18 Three
chemotherapeutics bearing pendant alcohols were derivatized as prodrugs with acrylates
containing acid-labile silyl ether linkages for incorporation into cationic PEG-based
hydrogel NPs.19
Small interfering RNA (siRNA) oligonucleotides have been loaded into PLGA and hydrogel
NPs through physical entrapment and reversible covalent incorporation. For PLGA, the
molecular weight and lactide:glycolide ratio influenced the encapsulation efficiency of
siRNA, reaching 46% in 80×320 nm rod-shaped NPs.20 For hydrogel NPs, a delivery sheet
of siRNA (in native or macromer form) and hydrophilic acrylate precursors (cationic,
fluorescent, and PEGs) were married to PRINT molds through lamination followed by
photochemical curing to provide electrostatic or covalent association of siRNA with NPs.21
In addition, RNA Replicon, an autonomously replicating RNA, has been loaded into bovine
serum albumin (BSA) protein-based particles for the development of vaccines.22 BSA-based
particles were loaded at 1 wt % with RNA Replicon, encoding a protein detectable through
ELISA. Proteins have also been loaded into extremely deformable hydrogel microparticles
for the purpose of artificial blood. Hemoglobin was stably and uniformly loaded into red
blood cell mimicking particles by covalent conjugation.23 High loadings of hemoglobin
were achieved in microgels with preservation of protein activity and particle deformability.
Enhanced efficacy of therapies could be realized by simultaneously loading multiple cargos
into PRINT particles. For example, a chemotherapeutic and siRNAs targeting anti-apoptotic
and angiogenic genes could be co-delivered to treat cancers.
IV. Controlling Release Profiles of Therapeutic Cargos for Particle-based
Drug Delivery
Controlled release of encapsulated therapeutics is crucial for improved efficacy and reduced
toxicity. The basic principle for controlled release is to ensure minimal pre-mature release
before reaching the site of activity but sufficient release after reaching the target, which can
be specific tissues, cells or cellular compartments. While external stimuli including light,
ultrasound, and magnetic fields have been applied to control release in other systems,
PRINT particle delivery systems mainly utilize molecular design of the drug and particle
matrix to synchronize the release profile with physiological conditions. Physiological
changes, including pH gradient and redox states, have been utilized to trigger release of
therapeutic cargos from PRINT particles at a desired site.19
The well-studied silyl ether protecting groups for hydroxyls have been incorporated into the
particle matrix for creating acid-labile crosslinkers,19 for which the degradation profile can
be easily tuned by varying bulkiness of alkyl substituent on the silicon atom. The amount
and type of the silyl ether crosslinker incorporated in the particle composition determined
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the degradation rate of the particle matrices, allowing for control over the release rate of
encapsulated therapeutics from hours to months. For drugs that are difficult to retain in
intrinsically porous hydrogel particles, a silyl ether based pro-drug approach has been
developed. The pro-drug can be polymerized into PRINT particles, releasing drugs at
different rates depending on the silicon substituent and pH. In vitro experiments
demonstrated that particles could be fabricated to release drugs, like gemcitabine and
camptothecin, rapidly and with comparable toxicities to the free drug.19
The reducing environment of the cytoplasm of cells can also be taken advantage of for
controlled release of therapeutics. The high concentration of reduced glutathione in the
cytoplasm, compared to the extracellular environment, can degrade the disulfide bond,
which is widely used to fabricate degradable particles.22 The disulfide strategy has been
applied to both hydrogel and protein-based PRINT particles. We demonstrated the reductive
release of doxorubicin and resulting in vitro cell death in a cancer cell line from hydrogel
PRINT particles crosslinked by a commercially available disulfide-containing crosslinker,
while control particles crosslinked by a non-degradable crosslinker elicited no
cytotoxicity.17 Similar to a pro-drug approach, siRNA was linked to an acrylate group
through disulfide linkage and polymerized into hydrogel NPs.21 The siRNA cargo was
found to be adequately protected by the particle matrix and only be released upon exposure
to a reducing environment for effective gene knockdown in vitro compared to a non-
degradable control siRNA macromer. In BSA-based PRINT particles loaded with RNA
replicon, premature dissolution of protein was eliminated by incorporating a newly
synthesized disulfide containing crosslinker. Bis(imidazole carboxylate) groups in the
crosslinker reacted with amines in the protein to crosslink the particles, rendering them
transiently insoluble.22 The crosslinked BSA particles preferentially dissolved under
reducing conditions, with the dissolution rate controlled by adjusting the crosslinker
concentration, and induced in vitro expression of protein.
Considering the abnormal vasculature and the prevalence of the EPR effect in tumors,
delivery vectors with physico-chemical and geometric properties designed to reach diseased
tissues should have high therapeutic indices and limited side effects. Bottom-up particle
fabrication approaches can exhibit interdependent properties on particle size, shape, and
surface chemistry; conversely, as a top-down fabrication technology, the PRINT platform
offers the opportunity to independently control particle properties, which can be designed
for delivery vectors to alleviate tumor burden and improve the quality of life for patients.
Given the range of cargos, dimensions, compositions, and surface properties attained with
PRINT particles, future biomedical endeavors may involve (1) exploring additional types of
therapeutic cargos that face difficulties being incorporated into conventional delivery
systems, (2) tuning vector dimensions, deformability, and composition to reach particular
tissues, allow for specific transport behavior, and deliver therapeutics to cells effectively, (3)
exploiting features of tissue environments, such as the presence of matrix metalloproteinases
and cathepsins in cancers for degradation of particles or release of cargo, and (4)
functionalizing the surface of particles with ligands to target endothelium or receptors on
target cells.
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(A) The IFP is uniformly elevated in tumors except at the margin. The steep drop in IFP at
the margin causes fluid, growth factors and cells to leak out of the tumor into the
peritumoral tissue, which in turn might facilitate angiogenesis and metastasis, and inhibit
drug delivery;1 (B) General properties of the tumor microenvironment, including
heterogeneous drug delivery. Three regions are present in many tumor types – the periphery,
seminecrotic region, and necrotic core.14 Adapted with permission from Nature Publishing
Group and Annual Reviews.
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Examples of therapeutic cargos and particle matrix components that may be mixed and
processed into PRINT molds to produce monodisperse, shape-specific particles. (a) A pre-
particle film (red) is married to PRINT molds (green) at elevated temperature followed by
solidification after cooling to room temperature. (b) Pre-particle solution (red) is laminated
into PRINT molds (green) followed by exposure to UV light for photochemical curing. (c)
Protein (red sphere) contains primary amine residues that are reacted with a disulfide-
containing bis(imidazole carboxylate) (DIC) crosslinker. (d) PLGA-siRNA NPs on
harvesting layer of poly(vinyl alcohol) (PVA) (yellow) are collected in solution with
cationic and endosomolytic lipids. (e) Lysine residues on hemoglobin are coupled to
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carboxylic acid-containing hydrogel microparticles through amidation. SEM micrographs
illustrate the morphology of DIC-crosslinked BSA-Replicon microparticles (scale bar = 5
µm), lipid-coated, rod-shaped PLGA particles (scale bar = 2 µm), and gemcitabine prodrug
PEG NPs (scale bar = 1 µm).19–20,22 Adapted with permission from the American Chemical
Society. Copyright 2011 and 2012 American Chemical Society.
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